ocr: Tumor heterogeneity: Is the assay endpoint selective for malignant cells versus stromal cells? Is the assessability rate greater than 80%? Have the assays been correlated with clinical response and survival? Can the tests evaluate all histologic types, or are they restricted to only some types of tumors? Are clinically appropriate drugs evaluated in the test? Does the turnaround time meet clincial requirements? Is the test information easily interpreted and applied? Is the test cost-eflective?
